AMGN
Price
$263.23
Change
-$0.84 (-0.32%)
Updated
Apr 18, 2:04 PM EST
14 days until earnings call
BIIB
Price
$190.84
Change
-$1.32 (-0.69%)
Updated
Apr 18, 2:17 PM EST
6 days until earnings call
Ad is loading...

Analysis and predictions AMGN vs BIIB

Header iconAMGN vs BIIB Comparison
Open Charts AMGN vs BIIBBanner chart's image
Amgen
Price$263.23
Change-$0.84 (-0.32%)
Volume$1K
CapitalizationN/A
Biogen
Price$190.84
Change-$1.32 (-0.69%)
Volume$800
CapitalizationN/A
View a ticker or compare two or three
AMGN vs BIIB Comparison Chart

Loading...

AMGNDaily Signal changed days agoGain/Loss if shorted
 
Show more...
BIIBDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
AMGN vs. BIIB commentary
Apr 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a StrongSell and BIIB is a Hold.

COMPARISON
Comparison
Apr 18, 2024
Stock price -- (AMGN: $264.07 vs. BIIB: $192.16)
Brand notoriety: AMGN and BIIB are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: AMGN: 81% vs. BIIB: 104%
Market capitalization -- AMGN: $151.69B vs. BIIB: $31.34B
AMGN [@Pharmaceuticals: Major] is valued at $151.69B. BIIB’s [@Pharmaceuticals: Major] market capitalization is $31.34B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMGN’s FA Score shows that 3 FA rating(s) are green whileBIIB’s FA Score has 1 green FA rating(s).

  • AMGN’s FA Score: 3 green, 2 red.
  • BIIB’s FA Score: 1 green, 4 red.
According to our system of comparison, AMGN is a better buy in the long-term than BIIB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMGN’s TA Score shows that 2 TA indicator(s) are bullish while BIIB’s TA Score has 3 bullish TA indicator(s).

  • AMGN’s TA Score: 2 bullish, 5 bearish.
  • BIIB’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, BIIB is a better buy in the short-term than AMGN.

Price Growth

AMGN (@Pharmaceuticals: Major) experienced а -0.89% price change this week, while BIIB (@Pharmaceuticals: Major) price change was -4.66% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -2.79%. For the same industry, the average monthly price growth was -4.80%, and the average quarterly price growth was -2.14%.

Reported Earning Dates

AMGN is expected to report earnings on Jul 30, 2024.

BIIB is expected to report earnings on Jul 23, 2024.

Industries' Descriptions

@Pharmaceuticals: Major (-2.79% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
A.I.dvisor published
a Summary for AMGN with price predictions.
OPEN
A.I.dvisor published
a Summary for BIIB with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
AMGN($152B) has a higher market cap than BIIB($31.3B). BIIB has higher P/E ratio than AMGN: BIIB (26.95) vs AMGN (22.66). AMGN YTD gains are higher at: -7.602 vs. BIIB (-25.741). AMGN has higher annual earnings (EBITDA): 14.8B vs. BIIB (2.04B). AMGN has more cash in the bank: 10.9B vs. BIIB (1.05B). BIIB has less debt than AMGN: BIIB (7.34B) vs AMGN (64.6B). AMGN has higher revenues than BIIB: AMGN (28.2B) vs BIIB (9.84B).
AMGNBIIBAMGN / BIIB
Capitalization152B31.3B486%
EBITDA14.8B2.04B726%
Gain YTD-7.602-25.74130%
P/E Ratio22.6626.9584%
Revenue28.2B9.84B287%
Total Cash10.9B1.05B1,038%
Total Debt64.6B7.34B880%
FUNDAMENTALS RATINGS
AMGN vs BIIB: Fundamental Ratings
AMGN
BIIB
OUTLOOK RATING
1..100
7251
VALUATION
overvalued / fair valued / undervalued
1..100
18
Undervalued
96
Overvalued
PROFIT vs RISK RATING
1..100
18100
SMR RATING
1..100
1277
PRICE GROWTH RATING
1..100
5865
P/E GROWTH RATING
1..100
4916
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AMGN's Valuation (18) in the Biotechnology industry is significantly better than the same rating for BIIB (96). This means that AMGN’s stock grew significantly faster than BIIB’s over the last 12 months.

AMGN's Profit vs Risk Rating (18) in the Biotechnology industry is significantly better than the same rating for BIIB (100). This means that AMGN’s stock grew significantly faster than BIIB’s over the last 12 months.

AMGN's SMR Rating (12) in the Biotechnology industry is somewhat better than the same rating for BIIB (77). This means that AMGN’s stock grew somewhat faster than BIIB’s over the last 12 months.

AMGN's Price Growth Rating (58) in the Biotechnology industry is in the same range as BIIB (65). This means that AMGN’s stock grew similarly to BIIB’s over the last 12 months.

BIIB's P/E Growth Rating (16) in the Biotechnology industry is somewhat better than the same rating for AMGN (49). This means that BIIB’s stock grew somewhat faster than AMGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMGNBIIB
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
56%
Bullish Trend 2 days ago
61%
Momentum
ODDS (%)
Bearish Trend 2 days ago
49%
Bearish Trend 2 days ago
61%
MACD
ODDS (%)
Bearish Trend 2 days ago
52%
Bearish Trend 2 days ago
73%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
57%
Bearish Trend 2 days ago
65%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
48%
Bearish Trend 2 days ago
63%
Advances
ODDS (%)
Bullish Trend 23 days ago
57%
N/A
Declines
ODDS (%)
Bearish Trend 4 days ago
54%
Bearish Trend 2 days ago
65%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
59%
Bullish Trend 2 days ago
63%
Aroon
ODDS (%)
Bearish Trend 2 days ago
47%
Bearish Trend 2 days ago
58%
View a ticker or compare two or three
Ad is loading...
AMGNDaily Signal changed days agoGain/Loss if shorted
 
Show more...
BIIBDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
YQ2.350.08
+3.52%
17 Education & Technology Group
ENIC2.900.08
+2.84%
Enel Chile SA
MLM592.92-2.32
-0.39%
Martin Marietta Materials
TRS25.04-0.17
-0.67%
TriMas Corp
RNGR10.85-0.28
-2.52%
Ranger Energy Services

AMGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, AMGN has been loosely correlated with GILD. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if AMGN jumps, then GILD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMGN
1D Price
Change %
AMGN100%
-0.59%
GILD - AMGN
46%
Loosely correlated
-0.56%
NVS - AMGN
34%
Loosely correlated
-0.13%
BIIB - AMGN
33%
Loosely correlated
-1.53%
JNJ - AMGN
33%
Poorly correlated
+0.22%
BMY - AMGN
32%
Poorly correlated
-0.87%
More

BIIB and

Correlation & Price change

A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with BMY. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then BMY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIIB
1D Price
Change %
BIIB100%
-1.53%
BMY - BIIB
39%
Loosely correlated
-0.87%
GILD - BIIB
39%
Loosely correlated
-0.56%
AMGN - BIIB
36%
Loosely correlated
-0.59%
OGN - BIIB
31%
Poorly correlated
+0.45%
PFE - BIIB
27%
Poorly correlated
-1.05%
More